{
    "clinical_study": {
        "@rank": "116020", 
        "biospec_descr": {
            "textblock": "no biospecimen collected"
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "This is an open-label, non-interventional, single-arm, multicenter study in a real-world\n      population to assess the clinically symptom improvement and quality of life (QoL) in\n      patients with locally advanced or metastatic NSCLC and positive EGFR mutation who receive\n      EGFR-TKIs as the first-line treatment.\n\n      The Primary Objective is to estimate symptom improvement rates in patients with locally\n      advanced or metastatic NSCLC and positive EGFR mutation who receive EGFR-TKIs as the\n      first-line treatment.  A clinically meaningful improvement is defined as an increase from\n      baseline of 2 or more points for LCS (Lung Cancer Scales) at Week 4."
        }, 
        "brief_title": "Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Small-Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The Secondary Objectives are:\n\n        1. To estimate symptom improvement rates at weeks 2 and 12\n\n        2. To estimate mean change from baseline in overall QoL scores using the FACT-L instrument\n           and LCS score at Week 2, 4 and 12.\n\n        3. To estimate the proportion of patients exhibiting an LCS change of 7 points or more at\n           weeks 2, 4 and 12.\n\n        4. Subgroup information of symptom improvement rate, QoL and disease-related symptom\n           scores by gender, smoking status, smoking pattern, WHO performance, number of\n           metastatic sites, female/never smokers and patients with COPD at week 2, week 4 and\n           week 12."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed with symptomatic, locally advanced or metastatic (stage IIIb/IV)\n             NSCLC.\n\n          -  Patients who are positive for EGFR mutation\n\n          -  Patients with a prescription of EGFR-TKI as their first-line treatment\n\n        Exclusion Criteria:\n\n        - Involvement in any planning and/or conduct of the clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "advanced NSCLC patients who will be treated as first line treatment with EGFR-TKI"
            }
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947868", 
            "org_study_id": "NIS-OTW-ATC-2013/1"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "contact": {
                "last_name": "Te-Chun Hsia", 
                "phone": "886422062121"
            }, 
            "facility": {
                "address": {
                    "city": "Taichung", 
                    "country": "Taiwan"
                }, 
                "name": "China Medical University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Non-interventional Evaluation of Symptoms Improvement of First-Line Therapy of EGFR Tyrosine Kinase Inhibitor in Advanced NSCLC Patients With Positive EGFR Mutation - the SMILE Study", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Wang", 
            "phone": "886223782390"
        }, 
        "overall_official": {
            "affiliation": "886422062121", 
            "last_name": "Te-Chun Hsia", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": ":n/a", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "LCS is Lung Cancer Scale", 
            "measure": "The proportion of patients demonstrating a clinically meaningful improvement post 4 weeks of EGFR-TKI therapy defined as an increase in LCS \u2265 2 points from baseline.", 
            "safety_issue": "No", 
            "time_frame": "15 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947868"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The proportion of patients demonstrating a clinically meaningful improvement post 2 weeks and 12 weeks of EGFR-TKI therapy as defined as an increase in LCS \u2265 2 points from baseline.", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "description": "FACT-L is Functional Assessment of Cancer Therapy-Lung questionnaire. TOI is Treatment Outcome Index. LCS is Lung Cancer Scale.", 
                "measure": "Mean change from baseline to Week 2, 4 and 12 in FACT-L, TOI and LCS.", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "description": "LCS is Lung Cancer Scale", 
                "measure": "The proportion of patients demonstrating a clinically meaningful improvement post 2, 4 and 12 weeks of EGFR-TKI therapy as defined as an increase in LCS \u2265 7 points from baseline.", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "measure": "Descriptive statistics in improvement rate (defined as LCS \u2265 2 points changed from baseline), QoL and disease-related symptom scores at week 2,4 and 12 and summarized by gender, smoking status, smoking pattern, WHO performance status, etc", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}